Hasta La Creative!

Call it a stroke of genius or perhaps walking on a thin line, advertising standard have always been known to lay down its groundwork as far as fulfilling requirements and making sure that brands are known and adhere to policies. But for some business wise cracks, holding back the brand and leaving it to be discovered through websites or other means of information providing seems to be the ploy of most companies to go around the buckle of advertising watchdogs today.

FDA rules state that if an advertisement does not name a drug directly, it does not need to include a listing of possible side effects. According to the Journal, the strategy is “gaining popularity” among drugmakers because listing the side effects “chew[s] up expensive television time.” For example, a 60-second ad for Eli Lilly’s osteoporosis drug Evista spends 25 seconds listing side effects.

(Source) Wall Street Journal

For companies, this is a good way to make the most out of ads without having to face possible sanctions and penalties. But it seems that branding has taken another route and from the looks of it, it may just work.

Brian Yalung is a Problogger at Talent Zoo mainly contributing to latest news and issues on advertising and marketing. The sites are as follows: www.beyondmadisonavenue.com, Talent Zoo is the #1 site for Ad, Marketing, and Media Professionals. Catch the Buzz at Beyond Madison Avenue!